Abiopharma

🔍 Russell Alan J (Executive)

Company: Edgewise Therapeutics, Inc. (EWTX)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 5,781 shares of Common Stock (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 30,336.00 | transaction_form_type: 4
• Acquired 7,031 shares of Common Stock (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 37,367.00 | transaction_form_type: 4
• Sold 3,238 shares of Common Stock at $43.6775 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 34,129.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,273 shares of Common Stock at $43.6759 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 31,856.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 390 shares of Common Stock at $44.46 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 31,466.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,781 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2034-08-12 | equity_swap_involved: false | shares_owned_after: 11,563.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 7,031 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2035-08-12 | equity_swap_involved: false | shares_owned_after: 21,094.00 | transaction_form_type: 4 | Footnotes: F5
• Acquired 32,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-08-12 | equity_swap_involved: false | shares_owned_after: 32,500.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 65,000 shares of Stock Option (Right to Buy) (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-08-12 | equity_swap_involved: false | shares_owned_after: 65,000.00 | transaction_form_type: 4 | Footnotes: F7

Footnotes:

• F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
• F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
• F5: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
• F6: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
• F7: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.